{"protocolSection":{"identificationModule":{"nctId":"NCT00686959","orgStudyIdInfo":{"id":"11514"},"secondaryIdInfos":[{"id":"H3E-MC-JMIG","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","officialTitle":"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology","acronym":"PROCLAIM"},"statusModule":{"statusVerifiedDate":"2016-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-09"},"primaryCompletionDateStruct":{"date":"2014-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-11","type":"ACTUAL"},"studyFirstSubmitDate":"2008-05-28","studyFirstSubmitQcDate":"2008-05-28","studyFirstPostDateStruct":{"date":"2008-05-30","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-10-22","resultsFirstSubmitQcDate":"2015-10-22","resultsFirstPostDateStruct":{"date":"2015-11-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-05-20","lastUpdatePostDateStruct":{"date":"2016-06-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":598,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A: Pemetrexed + Cisplatin and TRT","type":"EXPERIMENTAL","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 milligrams per meter squared (mg/m\\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.\n\nCisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \\[Gy\\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Radiation: Thoracic Radiation Therapy (TRT)"]},{"label":"Arm B: Etoposide + Cisplatin and TRT","type":"ACTIVE_COMPARATOR","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22","interventionNames":["Drug: Cisplatin","Drug: Etoposide","Drug: Vinorelbine","Drug: Paclitaxel","Drug: Carboplatin","Radiation: Thoracic Radiation Therapy (TRT)"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"infusion over 10 minutes","armGroupLabels":["Arm A: Pemetrexed + Cisplatin and TRT"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Cisplatin","description":"infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines","armGroupLabels":["Arm A: Pemetrexed + Cisplatin and TRT","Arm B: Etoposide + Cisplatin and TRT"]},{"type":"DRUG","name":"Etoposide","description":"administered per local practice guidelines over a minimum of 30 minutes","armGroupLabels":["Arm B: Etoposide + Cisplatin and TRT"]},{"type":"DRUG","name":"Vinorelbine","description":"administered over 6-10 minutes infusion per local practice guidelines","armGroupLabels":["Arm B: Etoposide + Cisplatin and TRT"]},{"type":"DRUG","name":"Paclitaxel","description":"administered as a 3-hour infusion","armGroupLabels":["Arm B: Etoposide + Cisplatin and TRT"]},{"type":"DRUG","name":"Carboplatin","description":"administered per local practice guidelines over 30 minutes","armGroupLabels":["Arm B: Etoposide + Cisplatin and TRT"]},{"type":"RADIATION","name":"Thoracic Radiation Therapy (TRT)","armGroupLabels":["Arm A: Pemetrexed + Cisplatin and TRT","Arm B: Etoposide + Cisplatin and TRT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival","description":"Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.","timeFrame":"Baseline to Date of Death from Any Cause (Up to 71.4 Months)"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) time is from baseline to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have died or to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.","timeFrame":"Baseline to Measured Progressive Disease or Death from Any Cause (Up to 66.6 Months)"},{"measure":"Objective Response Rate (Complete Response [CR] + Partial Response [PR])","description":"Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.","timeFrame":"Baseline to Measured Progressive Disease (Up to 7 Months)"},{"measure":"Survival Rates at 1, 2, and 3 Years","description":"The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.","timeFrame":"Baseline to Date of Death from Any Cause (Up to 71.4 Months)"},{"measure":"First Site of Disease Failure in Terms of Relapse","description":"The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.","timeFrame":"Baseline to Relapse (Up to 66.6 Months)"},{"measure":"Percentage of Participants With a Post Baseline Swallowing Diary Score >=4","description":"Participants were provided with a swallowing diary to record issues with swallowing using a 5-point categorical scale: (1) no problems; (2) mild soreness; (3) swallowing solids with some difficulty; (4) inability to swallow solids; and (5) inability to swallow liquids. Participants rated swallowing over the previous 24 hours. The percentage of participants was calculated by dividing the number of with a post baseline swallowing diary score \\>=4 by total number of participants analyzed, multiplied by 100. No adjustments were made for the number of available assessments nor were any interpolation of missing assessments made.","timeFrame":"Baseline through 30 Days Post Study"}],"otherOutcomes":[{"measure":"Adverse Events: The Number of Deaths Per Treatment Group","description":"The number of deaths that occurred while on study drug, the number of deaths due to adverse events (AEs) while on study drug, and the number of deaths due to the study disease (that is, disease progression) while on study drug are presented. In addition, the number of deaths within 30 days of treatment discontinuation, the number of deaths due to AEs within 30 days of treatment discontinuation, and the number of deaths due to study disease within 30 days of treatment discontinuation are presented. For both the deaths due to AEs that occurred on study and for deaths due to AEs that occurred within 30 days of treatment discontinuation, the causality (events assess as possibly related \\[poss related\\] to study drug per investigator judgement) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 30 Days Post Study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have Stage IIIA or IIIIB NSCLC of the non-squamous type\n* Participants must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated on computerized tomography (CT) scan\n* Participants must be physically mobile, take care of themselves and must be up and about and able to perform light activities, such as light housework or office work\n* Participants must be 18 years of age or older\n* Participants must have lost no more than 10% of their body weight in the previous 3 months\n* Women must be sterile, postmenopausal, or on contraception, and men must be sterile or on contraception\n* Participants' test results assessing the function of their blood forming tissue, kidneys, liver, and lungs must be satisfactory\n* Participants with Stage IIIB NSCLC who have supraclavicular nodal involvement may be entered into this study. However, participants with cervical nodes are not permitted. The upper border of supraclavicular nodes must not extend above the upper border of the lateral end of the clavicle, extended medially.\n\nExclusion Criteria:\n\n* Participants cannot have other on-going (uncontrolled) illnesses, including active infections, recent heart problems, or psychiatric illnesses\n* Participants who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication\n* Participants who have had a heart attack (myocardial infarction) or other cardiac issues within 6 months of the trial\n* Participants who have received other investigational drugs within the last 30 days\n* Participants who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents\n* Participants who have diseases considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors\n* Participants who had prior thoracic radiation. However, other prior radiotherapy is allowed. Participants must have recovered from the toxic effects of the treatment prior to study enrollment. Participants may not have received whole pelvis radiation or radiation to more than 25% of their bone marrow. Prior radiotherapy must have been completed at least 30 days prior to study treatment.\n* Participants who have a radiation treatment plan that would expose more than 35% of the volume of their lung to 20 gray (Gy) or more of radiation\n* Participants who have concurrent cancer from another primary site requiring treatment of any kind within the past 5 years. Exemptions to this will be permitted on a case-by-case basis after prior approval by the Sponsor physician or designate if the investigator believes the participant's risk of recurrence and death is very low. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed. Participants with recurrence of a previously resected lung cancer or who have a second primary lung cancer are ineligible.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Birmingham","state":"Alabama","zip":"35249","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tucson","state":"Arizona","zip":"85704","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Thomasville","state":"Georgia","zip":"31792","country":"United States","geoPoint":{"lat":30.83658,"lon":-83.97878}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Quincy","state":"Illinois","zip":"62301","country":"United States","geoPoint":{"lat":39.9356,"lon":-91.40987}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Evansville","state":"Indiana","zip":"47713","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Indianapolis","state":"Indiana","zip":"46237","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Albany","state":"Indiana","zip":"47150","country":"United States","geoPoint":{"lat":38.28562,"lon":-85.82413}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.04056,"lon":-94.6169}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Louisville","state":"Kentucky","zip":"40402","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbia","state":"Maryland","zip":"21044","country":"United States","geoPoint":{"lat":39.24038,"lon":-76.83942}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fairhaven","state":"Massachusetts","zip":"02719","country":"United States","geoPoint":{"lat":41.6376,"lon":-70.90365}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ann Arbor","state":"Michigan","zip":"48106","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kansas City","state":"Missouri","zip":"64132","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fargo","state":"North Dakota","zip":"58122","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Longview","state":"Texas","zip":"75601","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Odessa","state":"Texas","zip":"79761","country":"United States","geoPoint":{"lat":31.84568,"lon":-102.36764}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Marcos","state":"Texas","zip":"78666","country":"United States","geoPoint":{"lat":29.88327,"lon":-97.94139}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sherman","state":"Texas","zip":"75090","country":"United States","geoPoint":{"lat":33.63566,"lon":-96.60888}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita Falls","state":"Texas","zip":"76310","country":"United States","geoPoint":{"lat":33.91371,"lon":-98.49339}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Burlington","state":"Vermont","zip":"05405","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Spokane","state":"Washington","zip":"99220","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Buenos Aires","zip":"C1188AAF","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wollongong","state":"New South Wales","zip":"2500","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Launceston","state":"Tasmania","zip":"7250","country":"Australia","geoPoint":{"lat":-41.43876,"lon":147.13467}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Antwerp","zip":"2020","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Haine-St.- Paul","zip":"7100","country":"Belgium"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Namur","zip":"5000","country":"Belgium","geoPoint":{"lat":50.4669,"lon":4.86746}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Turnhout","zip":"2300","country":"Belgium","geoPoint":{"lat":51.32254,"lon":4.94471}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barretos","zip":"14784700","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Curitiba","zip":"81520-060","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Porto Alegre","zip":"90610-970","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rio de Janeiro","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"São Paulo","zip":"01246000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Newmarket","state":"Ontario","zip":"L3Y2P9","country":"Canada","geoPoint":{"lat":44.05011,"lon":-79.46631}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Montreal","state":"Quebec","zip":"H3G 1A4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guangzhou","zip":"510060","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jinan","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":35.1221,"lon":105.48032}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wuhan","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bayonne","zip":"64100","country":"France","geoPoint":{"lat":43.49316,"lon":-1.473}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lille","zip":"59020","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75475","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cologne","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankfurt","zip":"60596","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rheine","zip":"48431","country":"Germany","geoPoint":{"lat":52.28509,"lon":7.44055}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","zip":"18537","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pátrai","zip":"26500","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bangalore","zip":"560 027","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hyderabaad","zip":"500024","country":"India"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jaipur","zip":"302016","country":"India","geoPoint":{"lat":26.91962,"lon":75.78781}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kolkata","zip":"700029","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madurai","zip":"625020","country":"India","geoPoint":{"lat":9.919,"lon":78.11953}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mumbai","zip":"400053","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Trivandrum","zip":"695011","country":"India","geoPoint":{"lat":8.4855,"lon":76.94924}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"'s-Hertogenbosch","zip":"5223 GZ","country":"Netherlands","geoPoint":{"lat":51.69917,"lon":5.30417}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Amsterdam","zip":"1081 HV","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Breda","zip":"4818 CK","country":"Netherlands","geoPoint":{"lat":51.58656,"lon":4.77596}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lisbon","zip":"1649-035","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Santa Maria da Feira","zip":"4520-211","country":"Portugal","geoPoint":{"lat":40.92726,"lon":-8.54839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vila Franca de Xira","zip":"4434-502","country":"Portugal","geoPoint":{"lat":38.95525,"lon":-8.98966}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Incheon","zip":"405-760","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"139-706","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Badalona","zip":"08915","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Elche","zip":"03202","country":"Spain","geoPoint":{"lat":38.26218,"lon":-0.70107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"L'Hospitalet de Llobregat","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Majadahonda","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Terrassa","zip":"08227","country":"Spain","geoPoint":{"lat":41.56667,"lon":2.01667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kaohsiung City","zip":"813","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kuei Shan Hsiang","zip":"33305","country":"Taiwan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fatih","zip":"34098","country":"Turkey (Türkiye)","geoPoint":{"lat":39.94548,"lon":32.87302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gaziantep","zip":"27310","country":"Turkey (Türkiye)","geoPoint":{"lat":37.05944,"lon":37.3825}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Melikgazi","zip":"38039","country":"Turkey (Türkiye)","geoPoint":{"lat":38.72455,"lon":36.21708}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Umuttepe","zip":"41380","country":"Turkey (Türkiye)","geoPoint":{"lat":39.12576,"lon":44.06198}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edgbaston","state":"Birmingham","zip":"B15 2TH","country":"United Kingdom","geoPoint":{"lat":52.4623,"lon":-1.92115}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","state":"Greater London","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edinburgh","state":"Scotland","zip":"EH4 2XU","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Manchester","state":"United Kingdom","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"31125266","type":"DERIVED","citation":"Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 Oct;35(10):1761-1767. doi: 10.1080/03007995.2019.1623185. Epub 2019 Jul 5."},{"pmid":"29976505","type":"DERIVED","citation":"Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S. Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934. doi: 10.1016/j.ijrobp.2018.04.015. Epub 2018 Apr 12."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 milligrams per meter squared (mg/m\\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.\n\nCisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \\[Gy\\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"FG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"301"},{"groupId":"FG001","numSubjects":"297"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"283"},{"groupId":"FG001","numSubjects":"272"}]},{"type":"Entered Consolidation Phase","achievements":[{"groupId":"FG000","numSubjects":"229"},{"groupId":"FG001","numSubjects":"202"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Study completion includes death due to any cause","numSubjects":"177"},{"groupId":"FG001","comment":"Study completion includes death due to any cause.","numSubjects":"180"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"124"},{"groupId":"FG001","numSubjects":"117"}]}],"dropWithdraws":[{"type":"Participants censored (no death events)","reasons":[{"groupId":"FG000","numSubjects":"124"},{"groupId":"FG001","numSubjects":"117"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants","groups":[{"id":"BG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"BG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"297"},{"groupId":"BG002","value":"598"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.1","spread":"9.6"},{"groupId":"BG001","value":"58.5","spread":"9.4"},{"groupId":"BG002","value":"58.8","spread":"9.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"243"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"355"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"27"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"217"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"421"}]}]},{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"122"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"West Asian","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}]},{"title":"Missing (unknown)","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"134"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"19"}]}]},{"title":"Portugal","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"18"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"65"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}]}]},{"title":"Greece","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"}]}]},{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"26"}]}]},{"title":"Netherlands","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"46"}]}]},{"title":"Turkey","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}]},{"title":"Ireland","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"61"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"25"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"17"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"37"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"ECOG performance status","description":"Eastern Cooperative Oncology Group (ECOG) performance status:\n\n0=Fully active, able to carry on all pre-disease performance without restriction\n\n1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as, light housework, office work","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"293"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"301"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Disease stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage IIIA - the cancer has spread to nearby tissue or spread to far away lymph nodes; Stage IIIB - cancer spread to opposite side of chest, more than one tumor within same lobe of lung.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"282"}]}]},{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"313"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Histology","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"226"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"452"}]}]},{"title":"Large cell carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"37"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"107"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Smoking status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never smoked","categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"108"}]}]},{"title":"Moderate smoker","categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"80"}]}]},{"title":"Heavy smoker","categories":[{"measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"183"},{"groupId":"BG002","value":"373"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}]}]}]},{"title":"Baseline PET scan","description":"Participant had a baseline Positron Emission Tomography (PET) scan for staging","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"250"},{"groupId":"BG001","value":"241"},{"groupId":"BG002","value":"491"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"107"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.","populationDescription":"All randomized participants. Arm A had 124 participants censored and Arm B had 117 participants censored.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Date of Death from Any Cause (Up to 71.4 Months)","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.81","lowerLimit":"20.40","upperLimit":"30.92"},{"groupId":"OG001","value":"24.97","lowerLimit":"22.18","upperLimit":"29.83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.831","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.20"}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) time is from baseline to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have died or to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.","populationDescription":"All randomized participants. Arm A had 99 participants censored and Arm B had 87 participants censored.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Measured Progressive Disease or Death from Any Cause (Up to 66.6 Months)","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.37","lowerLimit":"10.25","upperLimit":"13.21"},{"groupId":"OG001","value":"9.76","lowerLimit":"8.38","upperLimit":"11.73"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.130","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.04"}]},{"type":"SECONDARY","title":"Objective Response Rate (Complete Response [CR] + Partial Response [PR])","description":"Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Measured Progressive Disease (Up to 7 Months)","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","lowerLimit":"30.46","upperLimit":"41.58"},{"groupId":"OG001","value":"33.0","lowerLimit":"27.67","upperLimit":"38.66"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.458","statisticalMethod":"Log Rank","ciNumSides":"TWO_SIDED"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events: The Number of Deaths Per Treatment Group","description":"The number of deaths that occurred while on study drug, the number of deaths due to adverse events (AEs) while on study drug, and the number of deaths due to the study disease (that is, disease progression) while on study drug are presented. In addition, the number of deaths within 30 days of treatment discontinuation, the number of deaths due to AEs within 30 days of treatment discontinuation, and the number of deaths due to study disease within 30 days of treatment discontinuation are presented. For both the deaths due to AEs that occurred on study and for deaths due to AEs that occurred within 30 days of treatment discontinuation, the causality (events assess as possibly related \\[poss related\\] to study drug per investigator judgement) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 30 Days Post Study","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"272"}]}],"classes":[{"title":"On study drug (total)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}]}]},{"title":"On study drug: Due to AE","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}]},{"title":"On study drug: Due to AE poss related","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"On study drug: Due to study disease","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Within 30 Days of Discontinuation (disc) (total)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}]}]},{"title":"Within 30 Days of Disc: Due to AE","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Within 30 Days of Disc: Due to AE poss related","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Within 30 Days of Disc: Due to study disease","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Survival Rates at 1, 2, and 3 Years","description":"The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.","populationDescription":"All randomized participants. Arm A had 124 participants censored and Arm B had 117 participants censored.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"probability of survival","timeFrame":"Baseline to Date of Death from Any Cause (Up to 71.4 Months)","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}]}],"classes":[{"title":"1 year (12 months)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","lowerLimit":"0.70","upperLimit":"0.80"},{"groupId":"OG001","value":"0.77","lowerLimit":"0.72","upperLimit":"0.81"}]}]},{"title":"2 years (24 months)","categories":[{"measurements":[{"groupId":"OG000","value":"0.52","lowerLimit":"0.46","upperLimit":"0.58"},{"groupId":"OG001","value":"0.52","lowerLimit":"0.46","upperLimit":"0.58"}]}]},{"title":"3 years (36 months)","categories":[{"measurements":[{"groupId":"OG000","value":"0.40","lowerLimit":"0.34","upperLimit":"0.46"},{"groupId":"OG001","value":"0.37","lowerLimit":"0.31","upperLimit":"0.43"}]}]}]},{"type":"SECONDARY","title":"First Site of Disease Failure in Terms of Relapse","description":"The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.","populationDescription":"All randomized participants with objective PD.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Relapse (Up to 66.6 Months)","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"190"}]}],"classes":[{"title":"Relapsed within the radiation treatment field","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"30.0","upperLimit":"45.2"},{"groupId":"OG001","value":"45.8","lowerLimit":"38.6","upperLimit":"53.2"}]}]},{"title":"Relapsed inside thorax, outside of radiation field","categories":[{"measurements":[{"groupId":"OG000","value":"20.5","lowerLimit":"14.6","upperLimit":"27.4"},{"groupId":"OG001","value":"16.3","lowerLimit":"11.4","upperLimit":"22.4"}]}]},{"title":"Relapsed distant disease","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"42.2","upperLimit":"57.8"},{"groupId":"OG001","value":"45.8","lowerLimit":"38.6","upperLimit":"53.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Relapsed within the radiation treatment field","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.132","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG001"],"groupDescription":"Relapsed inside thorax, outside of radiation field","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.337","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"},{"groupIds":["OG000","OG001"],"groupDescription":"Relapsed distant disease","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.457","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Percentage of Participants With a Post Baseline Swallowing Diary Score >=4","description":"Participants were provided with a swallowing diary to record issues with swallowing using a 5-point categorical scale: (1) no problems; (2) mild soreness; (3) swallowing solids with some difficulty; (4) inability to swallow solids; and (5) inability to swallow liquids. Participants rated swallowing over the previous 24 hours. The percentage of participants was calculated by dividing the number of with a post baseline swallowing diary score \\>=4 by total number of participants analyzed, multiplied by 100. No adjustments were made for the number of available assessments nor were any interpolation of missing assessments made.","populationDescription":"All randomized participants with at least one post baseline swallowing diary score.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through 30 Days Post Study","groups":[{"id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT","description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"},{"id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"269"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"26.7","upperLimit":"37.5"},{"groupId":"OG001","value":"29.0","lowerLimit":"21.3","upperLimit":"31.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.150","statisticalMethod":"Fisher Exact","ciNumSides":"TWO_SIDED"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Randomized participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Arm A:","description":"Arm A: Participants were treated with pemetrexed plus cisplatin and concurrent thoracic radiation TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles.","seriousNumAffected":134,"seriousNumAtRisk":283,"otherNumAffected":279,"otherNumAtRisk":283},{"id":"EG001","title":"Arm B: Etoposide + Cisplatin and TRT","description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase","seriousNumAffected":145,"seriousNumAtRisk":272,"otherNumAffected":269,"otherNumAtRisk":272}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":22,"numAffected":5,"numAtRisk":272}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":283},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":272}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":283},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":272}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":11,"numAffected":1,"numAtRisk":272}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":8,"numAtRisk":283},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":272}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":272}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":4,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":272}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Endocarditis noninfective","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":9,"numAffected":1,"numAtRisk":272}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Aplasia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":1,"numAtRisk":272}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":11,"numAffected":1,"numAtRisk":272}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Aorto-oesophageal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":272}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":6,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":272}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":283},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":272}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Gastric perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Gastrointestinal angiodysplasia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Gastrointestinal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Intra-abdominal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":8,"numAtRisk":283},{"groupId":"EG001","numEvents":14,"numAffected":7,"numAtRisk":272}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":16,"numAffected":1,"numAtRisk":272}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Oesophageal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":26,"numAtRisk":283},{"groupId":"EG001","numEvents":89,"numAffected":29,"numAtRisk":272}]},{"term":"Oesophagitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":14,"numAtRisk":283},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":272}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":272}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":272}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":10,"numAffected":1,"numAtRisk":272}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":283},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":272}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Infectious colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":272}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":18,"numAtRisk":283},{"groupId":"EG001","numEvents":32,"numAffected":18,"numAtRisk":272}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":272}]},{"term":"Pneumonia haemophilus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":272}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Varicella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Radiation fibrosis - lung","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":7,"numAtRisk":283},{"groupId":"EG001","numEvents":20,"numAffected":13,"numAtRisk":272}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":7,"numAtRisk":283},{"groupId":"EG001","numEvents":13,"numAffected":5,"numAtRisk":272}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":14,"numAffected":1,"numAtRisk":272}]},{"term":"Stoma site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Tracheal haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":272}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":272}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":4,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":272}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":7,"numAtRisk":283},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":272}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":272}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":17,"numAffected":1,"numAtRisk":272}]},{"term":"Lung infiltration malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Paraneoplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":11,"numAffected":1,"numAtRisk":272}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":272}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":272}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Bronchial secretion retention","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":272}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":272}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":11,"numAffected":3,"numAtRisk":272}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":10,"numAffected":2,"numAtRisk":272}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":272}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":6,"numAtRisk":283},{"groupId":"EG001","numEvents":19,"numAffected":3,"numAtRisk":272}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":272}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":15,"numAffected":2,"numAtRisk":272}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":272}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":272}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":272}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":283},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":272}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":283},{"groupId":"EG001","numEvents":5,"numAffected":1,"numAtRisk":272}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":336,"numAffected":88,"numAtRisk":283},{"groupId":"EG001","numEvents":312,"numAffected":94,"numAtRisk":272}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":267,"numAffected":63,"numAtRisk":283},{"groupId":"EG001","numEvents":237,"numAffected":71,"numAtRisk":272}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":297,"numAffected":62,"numAtRisk":283},{"groupId":"EG001","numEvents":170,"numAffected":47,"numAtRisk":272}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":252,"numAffected":92,"numAtRisk":283},{"groupId":"EG001","numEvents":359,"numAffected":123,"numAtRisk":272}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":116,"numAffected":39,"numAtRisk":283},{"groupId":"EG001","numEvents":132,"numAffected":53,"numAtRisk":272}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":15,"numAtRisk":283},{"groupId":"EG001","numEvents":27,"numAffected":8,"numAtRisk":272}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":35,"numAtRisk":283},{"groupId":"EG001","numEvents":13,"numAffected":8,"numAtRisk":272}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":312,"numAffected":112,"numAtRisk":283},{"groupId":"EG001","numEvents":284,"numAffected":129,"numAtRisk":272}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":55,"numAtRisk":283},{"groupId":"EG001","numEvents":104,"numAffected":63,"numAtRisk":272}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":148,"numAffected":43,"numAtRisk":283},{"groupId":"EG001","numEvents":95,"numAffected":37,"numAtRisk":272}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":567,"numAffected":140,"numAtRisk":283},{"groupId":"EG001","numEvents":317,"numAffected":110,"numAtRisk":272}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":532,"numAffected":175,"numAtRisk":283},{"groupId":"EG001","numEvents":365,"numAffected":144,"numAtRisk":272}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":103,"numAffected":24,"numAtRisk":283},{"groupId":"EG001","numEvents":56,"numAffected":23,"numAtRisk":272}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":470,"numAffected":119,"numAtRisk":283},{"groupId":"EG001","numEvents":253,"numAffected":99,"numAtRisk":272}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":26,"numAtRisk":283},{"groupId":"EG001","numEvents":23,"numAffected":12,"numAtRisk":272}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":244,"numAffected":110,"numAtRisk":283},{"groupId":"EG001","numEvents":173,"numAffected":95,"numAtRisk":272}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":249,"numAffected":64,"numAtRisk":283},{"groupId":"EG001","numEvents":101,"numAffected":35,"numAtRisk":272}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":154,"numAffected":40,"numAtRisk":283},{"groupId":"EG001","numEvents":71,"numAffected":32,"numAtRisk":272}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":685,"numAffected":139,"numAtRisk":283},{"groupId":"EG001","numEvents":472,"numAffected":131,"numAtRisk":272}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":31,"numAtRisk":283},{"groupId":"EG001","numEvents":64,"numAffected":23,"numAtRisk":272}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":24,"numAtRisk":283},{"groupId":"EG001","numEvents":28,"numAffected":12,"numAtRisk":272}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":56,"numAtRisk":283},{"groupId":"EG001","numEvents":60,"numAffected":42,"numAtRisk":272}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":17,"numAtRisk":283},{"groupId":"EG001","numEvents":21,"numAffected":12,"numAtRisk":272}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":15,"numAtRisk":283},{"groupId":"EG001","numEvents":18,"numAffected":11,"numAtRisk":272}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":16,"numAtRisk":283},{"groupId":"EG001","numEvents":42,"numAffected":18,"numAtRisk":272}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":22,"numAtRisk":283},{"groupId":"EG001","numEvents":29,"numAffected":16,"numAtRisk":272}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":159,"numAffected":45,"numAtRisk":283},{"groupId":"EG001","numEvents":81,"numAffected":37,"numAtRisk":272}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":21,"numAtRisk":283},{"groupId":"EG001","numEvents":25,"numAffected":11,"numAtRisk":272}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":20,"numAtRisk":283},{"groupId":"EG001","numEvents":18,"numAffected":9,"numAtRisk":272}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":26,"numAtRisk":283},{"groupId":"EG001","numEvents":32,"numAffected":16,"numAtRisk":272}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":218,"numAffected":48,"numAtRisk":283},{"groupId":"EG001","numEvents":155,"numAffected":43,"numAtRisk":272}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":115,"numAffected":32,"numAtRisk":283},{"groupId":"EG001","numEvents":76,"numAffected":31,"numAtRisk":272}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":24,"numAtRisk":283},{"groupId":"EG001","numEvents":78,"numAffected":33,"numAtRisk":272}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":257,"numAffected":69,"numAtRisk":283},{"groupId":"EG001","numEvents":204,"numAffected":61,"numAtRisk":272}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":212,"numAffected":47,"numAtRisk":283},{"groupId":"EG001","numEvents":131,"numAffected":43,"numAtRisk":272}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":366,"numAffected":104,"numAtRisk":283},{"groupId":"EG001","numEvents":228,"numAffected":88,"numAtRisk":272}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":19,"numAtRisk":283},{"groupId":"EG001","numEvents":38,"numAffected":24,"numAtRisk":272}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":16,"numAtRisk":283},{"groupId":"EG001","numEvents":25,"numAffected":8,"numAtRisk":272}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":20,"numAtRisk":283},{"groupId":"EG001","numEvents":49,"numAffected":32,"numAtRisk":272}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":22,"numAtRisk":283},{"groupId":"EG001","numEvents":84,"numAffected":32,"numAtRisk":272}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":19,"numAtRisk":283},{"groupId":"EG001","numEvents":55,"numAffected":22,"numAtRisk":272}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":13,"numAtRisk":283},{"groupId":"EG001","numEvents":30,"numAffected":17,"numAtRisk":272}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":26,"numAtRisk":283},{"groupId":"EG001","numEvents":51,"numAffected":21,"numAtRisk":272}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":15,"numAtRisk":283},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":272}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":11,"numAtRisk":283},{"groupId":"EG001","numEvents":30,"numAffected":14,"numAtRisk":272}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":152,"numAffected":50,"numAtRisk":283},{"groupId":"EG001","numEvents":96,"numAffected":45,"numAtRisk":272}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":31,"numAtRisk":283},{"groupId":"EG001","numEvents":60,"numAffected":22,"numAtRisk":272}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":36,"numAtRisk":283},{"groupId":"EG001","numEvents":67,"numAffected":34,"numAtRisk":272}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":14,"numAtRisk":283},{"groupId":"EG001","numEvents":64,"numAffected":25,"numAtRisk":272}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":23,"numAtRisk":283},{"groupId":"EG001","numEvents":61,"numAffected":21,"numAtRisk":272}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":17,"numAtRisk":283},{"groupId":"EG001","numEvents":35,"numAffected":12,"numAtRisk":272}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":175,"numAffected":52,"numAtRisk":283},{"groupId":"EG001","numEvents":126,"numAffected":42,"numAtRisk":272}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":430,"numAffected":105,"numAtRisk":283},{"groupId":"EG001","numEvents":273,"numAffected":84,"numAtRisk":272}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":308,"numAffected":93,"numAtRisk":283},{"groupId":"EG001","numEvents":142,"numAffected":53,"numAtRisk":272}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":31,"numAtRisk":283},{"groupId":"EG001","numEvents":33,"numAffected":17,"numAtRisk":272}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":17,"numAtRisk":283},{"groupId":"EG001","numEvents":41,"numAffected":24,"numAtRisk":272}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":23,"numAtRisk":283},{"groupId":"EG001","numEvents":23,"numAffected":8,"numAtRisk":272}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":110,"numAffected":24,"numAtRisk":283},{"groupId":"EG001","numEvents":389,"numAffected":103,"numAtRisk":272}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":12,"numAtRisk":283},{"groupId":"EG001","numEvents":43,"numAffected":15,"numAtRisk":272}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":17,"numAtRisk":283},{"groupId":"EG001","numEvents":29,"numAffected":13,"numAtRisk":272}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":18,"numAtRisk":283},{"groupId":"EG001","numEvents":19,"numAffected":11,"numAtRisk":272}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":110,"numAffected":45,"numAtRisk":283},{"groupId":"EG001","numEvents":93,"numAffected":40,"numAtRisk":272}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":283},{"groupId":"EG001","numEvents":40,"numAffected":16,"numAtRisk":272}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Hungary","Mexico"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D005047","term":"Etoposide"},{"id":"D000077235","term":"Vinorelbine"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011034","term":"Podophyllotoxin"},{"id":"D013764","term":"Tetrahydronaphthalenes"},{"id":"D009281","term":"Naphthalenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D005960","term":"Glucosides"},{"id":"D006027","term":"Glycosides"},{"id":"D002241","term":"Carbohydrates"},{"id":"D014748","term":"Vinca Alkaloids"},{"id":"D046948","term":"Secologanin Tryptamine Alkaloids"},{"id":"D026121","term":"Indole Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D007211","term":"Indoles"},{"id":"D054836","term":"Indolizidines"},{"id":"D007212","term":"Indolizines"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}